Hypofibrinogenemia Clinical Trial
Official title:
The Role of Human Fibrinogen Concentrate (RiaSTAP) in Decreasing Blood Loss and the Need for Component Blood Therapy in Infants Undergoing Cardiopulmonary Bypass.
The goal of the study is to determine whether the use of Human Fibrinogen Concentrate (RiaSTAP) will decrease blood loss and the need for component blood therapy in neonates and infants undergoing cardiopulmonary bypass.
The goal of the study is to determine whether the use of Human Fibrinogen Concentrate (RiaSTAP) will decrease blood loss and the need for component blood therapy in neonates and infants undergoing cardiopulmonary bypass. RiaSTAP will be administered after termination of Cardiopulmonary Bypass (CPB) at a dose of 70 mg/kg, in a prospective, randomized, controlled study. We hypothesize that the administration of RiaSTAP in this manner will reduce peri-operative bleeding and transfusion requirements. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT00916656 -
Fibrinogen Concentrate (Human) - Efficacy and Safety Study
|
Phase 3 | |
| Completed |
NCT05780125 -
Effectiveness of Different Fibrinogen Preparations in Restoring Clot Firmness
|
Phase 2 | |
| Recruiting |
NCT03884725 -
Fibrinogen Concentrate In Children Cardiac Surgery 2
|
Phase 4 | |
| Recruiting |
NCT05634005 -
Clinical Decision Support for Blood Transfusions to Improve Guideline Adherence
|
N/A | |
| Withdrawn |
NCT04636268 -
FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis
|
Phase 3 | |
| Recruiting |
NCT05711524 -
Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding
|
Phase 4 |